Rocaglamide

SKU: orb1296181

Description

Rocaglamide

Research Area

Cell Biology, Metabolism Research, Signal Transduction

Images & Validation

−

Key Properties

−

CAS Number	84573-16-0
MW	505.56
Purity	99.37%
Formula	C₂₉H₃₁NO₇
SMILES	COc1ccc(cc1)[C@@]12Oc3cc(OC)cc(OC)c3[C@]1(O)[C@H](O)[C@@H]([C@H]2c1ccccc1)C(=O)N(C)C
Target	NF-κB,PERK,HSP
Solubility	Ethanol:5 mg/mL (9.89 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.98 mM);DMSO:10 mg/mL (19.78 mM)

Bioactivity

−

Target IC50	HSF1:50 nM
In Vivo	Tumor volumes in the Rocaglamide-treated group are 45±12% of those in the control group, indicating significant suppression of tumor growth. Rocaglamide treatment shows no reduction in body weight and no apparent signs of toxicity in the mice during the treatment . Read more...
In Vitro	Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC50 of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia [1,2,3]. Treatment with Rocaglamide alone leads to apoptosis in 9% HepG2 and 11% Huh-7 cells and treatment with TRAIL induces apoptosis in 16% HepG2 and 17% Huh-7 cells. However, the combination of Rocaglamide and TRAIL induces apoptosis in 55% HepG2 and 57% Huh-7 cells, which is evidently more than an additive effect . Read more...
Cell Research	HepG2 and Huh-7 cells (1×10^4/well) are seeded in 96-well plates in complete culture medium and incubated for 24 h. The cells are then exposed to 100 nM Rocaglamide and/or 100 ng/mL TRAIL for 24 h. The control cells are treated with DMSO at a concentration equal to that used for the drug-treated cells. The complete culture medium is then removed and MTT (200 μL, 0.5 mg/mL in 10% FBS-containing DMEM) is added to each well and the plate is incubated for 2 h at 37°C in a humidified incubator. The solution is then removed from the wells and 200 μL DMSO is added to each well prior to agitation. The absorbance at 570 nm is read using a microplate reader (Bio-Tek ELx800). The value for the vehicle-treated cells is considered to indicate 100% viability. Furthermore, a crystal violet assay is carried out. Briefly, the cells (1×10^5/mL) are seeded in a 12 well plate for 12 h and treated with TRAIL (0-100 ng/mL) and/or RocA(1-100 nM) for 12 h. The treated cells are washed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde for 15 min, and stained using crystal violet for a further 30 min . Read more...
Animal Research	The Huh-7 cells (3×10^6), suspended in 100 μL mix (equal volumes of DMEM and Matrigel), are implanted subcutaneously into the right flank of 10 female SCID mice (6-week-old) and then randomly divided into two equal groups, one of which received an intraperitoneal injection of Rocaglamide (2.5 mg/kg in 80 μL olive oil; n=5) and the other, used as a vehicle control, received olive oil alone (n=5). These treatments are performed once daily for 32 days and the tumor volumes and body weights of the animals are measured twice a week. The tumor volumes (mm3) are calculated using the following formula: Tumor volume=LS2/2, where L is the longest diameter and S is the shortest. At the end of the experiments, the mice are sacrificed and tumor samples are harvested, fixed in formalin and embedded in paraffin as tissue sections for immunohistochemical analysis . Read more...

Storage & Handling

−

Storage	store at low temperature \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Roc-A, Rocaglamide, Rocaglamide A, Eukaryotic Initiation Factor (eIF), eIF, HSP, HSF1, NF-kB, NFkB, NFκB, NF-κB

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID

331783 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

Rocaglamide (orb1296181)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

Purity:	99.83%
CAS Number:	1699754-37-4
MW:	505.56
Formula:	C₂₉H₃₁NO₇

Purity:	100.00%
CAS Number:	177262-30-5
MW:	477.51
Formula:	C₂₇H₂₇NO₇

CAS Number:	190385-15-0
MW:	478.49
Formula:	C₂₇H₂₆O₈

Purity:	>98% (HPLC)
CAS Number:	84573-16-0
MW:	505.56
Formula:	C₂₉H₃₁NO₇

Rocaglamide

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

(+)-Rocaglamide [orb3022448]

Didesmethylrocaglamide [orb1693474]

Rocagloic acid [orb2278595]

Rocaglamide [orb1217602]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

Rocaglamide (orb1296181)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors